National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry

New York, NY, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Following a challenge brought by Vertex Pharmaceuticals Incorporated, BBB National Programs’ National Advertising Division will refer claims made by Maze Therapeutics, Inc. to the appropriate regulatory authorities for review and possible enforcement action for failure to submit a substantive response to the National Advertising Division’s (NAD) inquiry. Vertex and Maze are competitors developing clinical-stage treatments for APOL1-Mediated Kidney Disease (AMK ...